Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 5 studies. This list may not include all unresolved or historical entries.

  • MK0663, etoricoxibRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • MK0663, etoricoxibRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • MK0663, etoricoxibRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • MK0663, etoricoxibRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • MK0663, etoricoxibRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 3
6
100%

Phase Distribution

0

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution6 total trials
Phase 3Large-scale testing
6(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 36 (100.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)

NCT00092703
completedphase_3

An Investigational Drug in Patients With Osteoarthritis (0663-073)

NCT00092755
completedphase_3

A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)

NCT00092768
completedphase_3

A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)

NCT00092781
completedphase_3

A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)

NCT00250445
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00092703Phase 3

Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)

Completed
NCT00092755Phase 3

An Investigational Drug in Patients With Osteoarthritis (0663-073)

Completed
NCT00092768Phase 3

A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)

Completed
NCT00092781Phase 3

A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)

Completed
NCT00250445Phase 3

A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)

Completed
NCT00092742Phase 3

Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)

Completed

All 6 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
6